Coeptis Therapeutics Holdings Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Coeptis Therapeutics Holdings, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue0.000.000.000.080.03
Cost of Revenue1.040.000.000.000.96
Gross Profit-1.040.000.000.08-0.93
Operating Expenses
Research & Development2.336.670.020.000.00
Selling, General & Administrative6.6813.3534.1814.125.78
Operating Expenses9.0221.4934.2014.125.78
Operating Income-10.05-21.49-34.20-14.05-6.71
Other Income/Expense
Interest Income0.000.000.000.000.00
Interest Expense0.40-0.110.220.19-0.15
Other Income/Expense-0.820.33-3.160.78-2.29
Income
Income Before Tax-10.88-21.27-37.57-13.45-9.16
Income Tax Expense0.000.000.000.000.00
Net Income-10.88-21.27-37.57-13.45-9.16
Net Income - Continuous Operations-10.88-21.27-37.57-13.450.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-9.44-20.49-36.35-12.81-6.39
EBIT-10.05-21.49-37.36-13.26-6.71
Depreciation & Amortization1.041.001.000.450.32
Earnings Per Share
Basic EPS-6.00-17.00-53.00-13.00-30.00
Diluted EPS-6.00-17.00-53.00-13.00-30.00
Basic Shares Outstanding1.931.280.711.020.30
Diluted Shares Outstanding1.931.280.711.020.30